{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:50:45Z","timestamp":1790214645442,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ymthe.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T20:08:37Z","timestamp":1617480517000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges"],"prefix":"10.1016","volume":"30","author":[{"given":"Annarita","family":"Miccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorana","family":"Ciura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edor","family":"Kabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.04.003_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2021.04.003_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal Muscular Atrophy: In the Challenge Lies a Solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymthe.2021.04.003_bib3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neuron.2018.02.009","article-title":"Augmenting the SMN Protein to Treat Infantile Spinal Muscular Atrophy","volume":"97","author":"Kim","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2021.04.003_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"12408","DOI":"10.1038\/ncomms12408","article-title":"Projected increase in amyotrophic lateral sclerosis from 2015 to 2040","volume":"7","author":"Arthur","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.04.003_bib8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/364362c0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"364","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.04.003_bib10","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0022-510X(97)00247-5","article-title":"The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies","volume":"152","author":"Gurney","year":"1997","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ymthe.2021.04.003_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.04.003_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.04.003_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.04.003_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.23946","article-title":"Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis","volume":"74","author":"Ciura","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/15548627.2016.1189070","article-title":"The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway","volume":"12","author":"Ciura","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.ymthe.2021.04.003_bib16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2021.04.003_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.04.003_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib21","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib22","article-title":"Onasemnogene Abeparvovec-xioi (ZOLGENSMA) in SMA 1 Patients","volume":"406","author":"Mendell","year":"2020","journal-title":"ASGCT Annual Meeting"},{"key":"10.1016\/j.ymthe.2021.04.003_bib23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib25","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene Therapy for ALS-A Perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2021.04.003_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.04.003_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.04.003_bib28","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.04.003_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nbt.2501","article-title":"Efficient genome editing in zebrafish using a CRISPR-Cas system","volume":"31","author":"Hwang","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.04.003_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.04.003_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1021\/acschembio.7b00710","article-title":"Editing the Genome Without Double-Stranded DNA Breaks","volume":"13","author":"Komor","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2021.04.003_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","article-title":"CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells","volume":"39","author":"Kurt","year":"2020","journal-title":"Nat Biotechnol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41467-018-04580-3","article-title":"In\u00a0vivo base editing of post-mitotic sensory cells","volume":"9","author":"Yeh","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.04.003_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.04.003_bib38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.yexcr.2007.10.012","article-title":"Genetic conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal muscular atrophy","volume":"314","author":"DiMatteo","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ymthe.2021.04.003_bib39","doi-asserted-by":"crossref","first-page":"165ra162","DOI":"10.1126\/scitranslmed.3004108","article-title":"Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy","volume":"4","author":"Corti","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib40","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1089\/hum.2017.255","article-title":"Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR\/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells","volume":"29","author":"Zhou","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.04.003_bib41","first-page":"15","article-title":"Disruption of splicing-regulatory elements using CRISPR\/Cas9 rescues spinal muscular atrophy in human iPSCs and mice","volume":"6","author":"Li","year":"2019","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.ymthe.2021.04.003_bib42","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41422-020-0304-y","article-title":"Base editing-mediated splicing correction therapy for spinal muscular atrophy","volume":"30","author":"Lin","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2021.04.003_bib43","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.3390\/ijms21113801","article-title":"CRISPR\/Cas9-Mediated Gene Correction to Understand ALS","volume":"21","author":"Yun","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2021.04.003_bib44","doi-asserted-by":"crossref","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In\u00a0vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2021.04.003_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2021.04.003_bib46","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a Mouse Model of ALS by In\u00a0Vivo Base Editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.003_bib47","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a Mouse Model of ALS by In\u00a0Vivo Base Editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.003_bib48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1905039","article-title":"Phenotype in an Infant with SOD1 Homozygous Truncating Mutation","volume":"381","author":"Andersen","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib49","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.molmed.2013.11.003","article-title":"TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?","volume":"20","author":"Vanden Broeck","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib50","doi-asserted-by":"crossref","first-page":"e1002214","DOI":"10.1371\/journal.pgen.1002214","article-title":"FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis","volume":"7","author":"Kabashi","year":"2011","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2021.04.003_bib51","article-title":"Crispr-cas9 targeted deletion of the c9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived ips cells","author":"Pribadi","year":"2016","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2021.04.003_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41467-017-02729-0","article-title":"C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity","volume":"9","author":"Selvaraj","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.04.003_bib53","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1073\/pnas.1901313116","article-title":"Partial inhibition of the overactivated Ku80-dependent DNA repair pathway rescues neurodegeneration in C9ORF72-ALS\/FTD","volume":"116","author":"Lopez-Gonzalez","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.04.003_bib54","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/hmg\/ddaa106","article-title":"Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR\/Cas9 genome editing using homology-directed repair","volume":"29","author":"Ababneh","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.04.003_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.stemcr.2020.01.010","article-title":"Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins","volume":"14","author":"Abo-Rady","year":"2020","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymthe.2021.04.003_bib56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2021.04.003_bib57","article-title":"CRISPR\/Cas9-Mediated Excision of ALS Causing Hexanucleotide Repeat Expansion in C9ORF72","volume":"Abstract 966","author":"Meijboom","year":"2020","journal-title":"ASGCT Annual Meeting 933"},{"key":"10.1016\/j.ymthe.2021.04.003_bib58","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","article-title":"Current Status and Challenges of DNA Base Editing Tools","volume":"28","author":"Jeong","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.003_bib59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41422-019-0267-z","article-title":"Reactivation of \u03b3-globin expression through Cas9 or base editor to treat \u03b2-hemoglobinopathies","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2021.04.003_bib60","doi-asserted-by":"crossref","first-page":"e3000686","DOI":"10.1371\/journal.pbio.3000686","article-title":"A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope","volume":"18","author":"Hu","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ymthe.2021.04.003_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.04.003_bib62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2021.04.003_bib63","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in\u00a0vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:03:49Z","timestamp":1761501829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621001908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1525001621001908"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.003","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}